

Appendix

Appendix Table A1. *PICOTS* table of study characteristics.

Metric	Inclusion	Exclusion
Population	Adults and children of all ages. Groups of interest include those living with or at risk for hypertension.	Non-human studies.
Intervention	Intervention or analysis related to screening, treatment, and management of hypertension. Specifically, interventions that: <ul style="list-style-type: none"> • Address management of chronic hypertension, or hypertension screening. • Encourage lifestyle modification (smoking, alcohol, diet, exercise, weight loss, sodium intake) as a way to manage hypertension. • Provide pharmacological treatment (ACE inhibitors, beta-blockers, combination therapy, etc.) • Improve access and affordability to hypertension diagnosis, treatment, and medication. • Involve community health workers (if cost data is included). • Note that studies or interventions to control hypertension may be referred to as cardiovascular disease prevention, CVD risk management, or similar terms. 	<ul style="list-style-type: none"> • Interventions designed for other diseases, for which hypertension may be a risk factor or common comorbidity but is not specifically evaluated. • Interventions for surgery patients and to address acute events related to hypertension, such as end stage renal disease, myocardial infarction, or angioplasty.
Comparator	Including comparative and non-comparative studies.	None.
Outcomes	Costs and/or benefits of hypertension intervention, treatment, or medication.	Looks only at economic cost, or opportunity cost, of hypertension. Studies to determine prevalence of hypertension alone. Studies assessing knowledge or awareness of hypertension.
Time Frame	Any publication dates.	None.
Settings	<ul style="list-style-type: none"> • Low- and middle-income countries. High-income countries in South America, Caribbean, and the Pacific. Reference: World Bank database. Include if it is not clear where the study takes place. • Take place in a clinical setting, i.e. facility-based services, not including acute care. • Include opportunistic screening at clinics, but not community screening campaigns 	Studies conducted in high income countries, or in territories or associated states of high-income countries (i.e. Marshall Islands, Puerto Rico, Bermuda)
Study Design	<ul style="list-style-type: none"> • Any study design dealing with analysis of costs, cost-benefit analysis, or cost effectiveness of hypertension related treatment or interventions. • Original research that reports primary data and studies using modeling with secondary data. 	Editorials, article or book reviews, correspondence. Abstracts related to study design and protocols.

	<ul style="list-style-type: none">• Systematic reviews.	
--	---	--

Appendix Table A2. Medical subject headings (MESH) and corresponding terms.

Hypertension	Blood Pressure, High; Blood Pressures, High; High Blood Pressure; High Blood Pressures
Drug Therapy	Therapy, Drug; Drug Therapies; Therapies, Drug; Chemotherapy; Chemotherapies; Pharmacotherapy; Pharmacotherapies
Diagnosis	Diagnoses; Diagnoses and Examinations; Examinations and Diagnoses; Postmortem Diagnosis; Diagnoses, Postmortem; Diagnosis, Postmortem; Postmortem Diagnoses; Antemortem Diagnosis; Antemortem Diagnoses; Diagnoses, Antemortem; Diagnosis, Antemortem
Mass Screening	Mass Screenings; Screening, Mass; Screenings, Mass; Screening; Screenings
Disease Management	Disease Managements; Management, Disease; Managements, Disease
Drug Combinations	Combinations, Drug
Cost and Cost Analysis	Costs, Cost Analysis; Cost, Cost Analysis; Costs and Cost Analyses; Cost Analysis; Analysis, Cost; Analyses, Cost; Cost Analyses; Cost; Comparison; Comparison, Cost; Comparisons, Cost; Cost Comparisons; Affordability; Affordabilities; Cost-Minimization Analysis; Analyses, Cost-Minimization; Analysis, Cost-Minimization; Cost Minimization Analysis; Cost-Minimization Analyses; Pricing; Cost; Costs; Cost Measures; Cost Measure; Measure, Cost; Measures, Cost
Cost Sharing	Sharing, Cost; Cost-Sharing Insurance; Cost Sharing Insurance; Insurance, Cost-Sharing
Cost Savings	Cost Savings; Saving, Cost; Savings, Cost
Cost of Illness	Illness Cost; Illness Costs; Sickness Cost; Costs, Sickness; Burden of Illness; Illness Burden; Illness Burdens; Cost of Disease; Economic Burden of Disease; Disease Cost; Cost, Disease; Costs, Disease; Disease Costs; Cost of Sickness; Sickness Costs; Costs of Disease
Economics	Consumer Price Index; Consumer Price Indices; Index, Consumer Price; Indices, Consumer Price; Consumption; Cost of Living; Living Cost; Living Costs; Easterlin Hypothesis; Hypothesis, Easterlin; Economic Conditions; Condition, Economic; Economic Condition; Conditions; Economic; Economic Policies; Policies, Economic; Policy, Economic; Economic Policy; Factors, Economic; Economic Factor; Factor, Economic; Economic Factors; Home Economics; Economics, Home; Household Consumption; Consumption, Household; Household Consumptions; Macroeconomic Factors; Factor, Macroeconomic; Factors, Macroeconomic; Microeconomic Factors; Factor, Microeconomic; Factors, Microeconomic; Production; Remittances; Remittance; Utility Theory; Theories, Utility; Theory, Utility; Utility Theories; Capital
Cost-Benefit Analysis	Analyses, Cost-Benefit; Analysis, Cost-Benefit; Cost-Benefit Analyses; Cost Benefit Analysis; Analyses, Cost Benefit; Analysis, Cost Benefit; Cost Benefit Analyses; Cost Effectiveness; Effectiveness, Cost; Cost-Benefit Data; Cost Benefit Data; Data, Cost-Benefit; Cost-Utility Analysis; Analyses, Cost-Utility; Analysis, Cost-Utility; Cost Utility Analysis; Cost-Utility Analyses; Economic Evaluation; Economic Evaluations; Evaluation, Economic; Evaluations, Economic; Marginal Analysis; Analyses, Marginal; Analysis, Marginal; Marginal Analyses; Cost Benefit; Costs and Benefits; Benefits and Costs; Cost-Effectiveness Analysis; Analysis, Cost-Effectiveness; Cost Effectiveness Analysis
Health Care Costs	Cost, Health Care; Costs, Health Care; Health Care Cost; Health Costs; Cost, Health; Costs, Health; Health Cost; Healthcare Costs; Cost, Healthcare; Costs, Healthcare; Healthcare Cost; Medical Care Costs; Costs, Medical Care; Cost, Medical Care; Medical Care Cost; Treatment Costs; Cost, Treatment; Costs, Treatment; Treatment Cost
Direct Service Costs	Costs, Direct Service; Service Costs, Direct; Cost, Direct Service; Direct Service Cost; Service Cost, Direct
Hospital Costs	Costs, Hospital; Hospital Cost; Cost, Hospital
Employer Health Costs	Health Costs, Employer; Employer Health Cost; Health Cost, Employer
Drug Costs	Cost, Drug; Costs, Drug; Drug Cost
Health Expenditures	Expenditure, Health; Health Expenditure; Expenditures, Health; Expenditures, Direct; Direct Expenditure; Direct Expenditures; Expenditure, Direct; Expenditures, Out-of-Pocket; Expenditure, Out-of-Pocket; Expenditures, Out of Pocket; Out-of-Pocket Expenditure; Out-of-Pocket Expenditures; Out-of-Pocket Payments; Out of Pocket Payments; Out-of-Pocket Payment; Payment, Out-of-Pocket; Payments, Out-of-Pocket; Out-of-Pocket Costs; Cost, Out-of-Pocket; Costs, Out-of-Pocket; Out of Pocket Costs; Out-of-Pocket Cost; Out-of-Pocket Spending; Out of Pocket Spending; Spending, Out-

	of-Pocket; Out-of Pocket Expenditures; Expenditure, Out-of Pocket; Expenditures, Out-of Pocket; Out of Pocket Expenditures; Out-of Pocket Expenditure; Out-of-Pocket Expenses; Expense, Out-of-Pocket; Expenses, Out-of-Pocket; Out of Pocket Expenses; Out-of-Pocket Expense; Expenditures; Expenditure; Expenditures, Indirect; Expenditure, Indirect; Indirect Expenditure; Indirect Expenditures
Health Services	Health Services Accessibility Availability of Health Services; Health Services Availability; Accessibility, Health Services; Access to Health Care; Accessibility of Health Services; Health Services Geographic Accessibility; Program Accessibility; Accessibility, Program; Contraceptive Availability; Availability, Contraceptive

Appendix Table A3. PubMed search history

Search	Query
#01	Search "Hypertension"[Mesh]
#02	Search (((("Drug Therapy"[Mesh]) OR "Diagnosis"[Mesh]) OR "Mass Screening"[Mesh]) OR "Disease Management"[Mesh] OR "Drug Combinations"[Mesh] OR "fixed-dose combination" OR "fixed dose combination")
#03	Search #1 AND #2
#04	Search ((chlorothiazide OR chlorthalidone OR hydrochlorothiazide OR polythiazide OR indapamide OR metolazone OR metolazone OR bumetanide OR furosemide OR torsemide OR amiloride OR triamterene OR eplerenone OR spironolactone))
#05	Search ((atenolol OR betaxolol OR bisoprolol OR metoprolol OR metoprolol extended release OR nadolol OR propranolol OR propranolol long-acting OR timolol OR acebutolol OR penbutolol OR pindolol OR carvedilol carvedilol OR labetalol))
#06	Search ((benazepril OR captopril OR enalapril OR fosinopril OR lisinopril OR moexipril OR perindopril OR quinapril OR ramipril OR trandolapril OR candesartan OR eprosartan OR irbesartan OR losartan OR olmesartan OR telmisartan OR valsartan))
#07	Search ((diltiazem extended release OR verapamil immediate release OR verapamil long acting OR verapamil OR amlodipine OR felodipine OR isradipine OR nicardipine sustained release OR nifedipine long-acting OR nisoldipine OR amlodipine OR felodipine OR isradipine OR nicardipine sustained release OR nifedipine long-acting OR nisoldipine))
#08	Search ((doxazosin OR prazosin OR terazosin OR clonidine OR clonidine patch OR methyl dopa OR reserpine OR guanfacine OR s hydralazine OR minoxidil OR sodium nitroprusside powder OR aspirin))
#09	#4 OR #5 OR #6 OR #7 OR #8
#10	#3 OR #9
#11	Search ((Africa or Asia or Caribbean or "West Indies" or "South America" or "Latin America" or "Central America"))
#12	Search ((Abkhazia or Afghanistan or Albania or Algeria or Angola or Antigua or Barbuda or Argentina or Armenia or Armenian or Artsakh or Aruba or Azerbaijan or Bahamas or Bangladesh or Barbados or Benin or Byelarus or Byelorussian or Belarus or Belorussian or Belorussia or Belize or Bermuda or Bhutan or Bolivia or Borneo or Bosnia or Herzegovina or Hercegovina or Botswana or Brasil or Brazil or Bulgaria or "Burkina Faso" or "Burkina Fasso" or "Upper Volta" or Burundi or Urundi or Cambodia or "Khmer Republic" or Kampuchea or Cameroon or Cameroons or Cameroon or Camerons or "Cape Verde" or "Cabo Verde" or "Central African Republic" or Chad or Chile or China or Colombia or Comoros or "Comoro Islands" or Comores or Congo or DRC or "Congo-Brazzaville" or "Congo-Kinshasa" or Zaire or "Cote d'Ivoire" or "Ivory Coast" or Cuba))
#13	Search ((Djibouti or "French Somaliland" or Dominica or "Dominican Republic" or "East Timor" or "East Timur" or "Timor Leste" or Ecuador or Egypt or "United Arab Republic" or "El Salvador" or Eritrea or Ethiopia or Fiji or Gabon or "Gabonese Republic" or Gambia or Gaza or Georgia or Georgian or Ghana or "Gold Coast" or Grenada or Guatemala or Guinea or Guiana or Guyana or Haiti or Honduras or India or Maldives or Indonesia or Iran or Iraq or Jamaica or Jordan or Kazakhstan or Kazakh or Kenya or Kiribati or Korea or DPRK or Kosovo or Kyrgyzstan or Kirghizia or "Kyrgyz Republic" or Kirghiz or Kirgizstan or "Lao PDR" or Laos or Lebanon or Lesotho or Basutoland or Liberia or Libya))
#14	Search (((Macedonia or FYROM or Macao or Madagascar or "Malagasy Republic" or Malaysia or Malaya or Malay or Sabah or Sarawak or Malawi or Nyasaland or Mali or "Marshall Islands" or Mauritania or Mauritius or "Agalega Islands" or Mexico or Micronesia or "Middle East" or Moldova or Moldavia or Moldovian or Mongolia or Montenegro or Morocco or Ifni or Mozambique or Myanmar or Myanma or Burma or Namibia or Nauru or Nepal or Nicaragua or Niger or Nigeria or Niue or Pakistan or Palau or Palestine or Panama or Paraguay or Peru or Philippines or Philipines or Phillipines or Phillippines or Poland or Polynesia or Portugal)))
#15	Search ((Romania or Rumania or Roumania or Russia or Russian or Rwanda or Ruanda or "Saint Kitts" or "St Kitts" or Nevis or "Saint Lucia" or "St Lucia" or "Saint Vincent" or "St Vincent" or Grenadines or Samoa or "Samoan Islands" or "Navigator Island" or "Navigator Islands" or "Sao Tome" or Principe or Senegal or Serbia or

	Montenegro or "Sierra Leone" or "Sri Lanka" or Ceylon or "Solomon Islands" or Somalia or Somaliland or "South Africa" or "South Ossetia" or Sudan or Suriname or Surinam or Swaziland or Syria or Tajikistan or Tadjikistan or Tadjikistan or Tadjik or Tanzania or Thailand or Tibet or Togo or "Togolese Republic" or Tokelau or Tonga or Transnistria or Trinidad or Tobago or Tunisia or Turkey or Turkmenistan or Turkmen or Tuvalu or Uganda or Ukraine or Uruguay or USSR or "Soviet Union" or "Union of Soviet Socialist Republics" or Uzbekistan or Uzbek or Vanuatu or "New Hebrides" or Venezuela or Vietnam or "Viet Nam" or "Mekong valley" or "Mekong delta" or "Western Sahara" or Sahrawi or "West Bank" or Yemen or Yugoslavia or Zambia or Zimbabwe or Zanzibar or Rhodesia)))
#16	Search (((developing or less* NEXT developed or "under developed" or underdeveloped or "middle income" or low* NEXT income or underserved or "under served" or deprived or poor*) NEXT (count* or nation* or population* or world)))
#17	Search ((developing or less* NEXT developed or "under developed" or underdeveloped or "middle income" or low* NEXT income) NEXT (economy or economies))
#18	Search ((low* NEXT (gdp or gnp or "gross domestic" or "gross national")))
#19	Search (low NEAR/3 middle NEAR/3 countr*)
#20	Search (((lmic or lmics or "third world" or "lami country" or "lami countries")))
#21	Search (((("transitional country" or "transitional countries")))
#22	#11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21
#23	Search ("Costs and Cost Analysis"[Mesh] OR "Cost Sharing"[Mesh] OR "Cost Savings"[Mesh] OR "Cost of Illness"[Mesh] OR "Economics"[Mesh] OR "Cost-Benefit Analysis"[Mesh] OR "Health Care Costs"[Mesh] OR "Direct Service Costs"[Mesh] OR "Hospital Costs"[Mesh] OR "Employer Health Costs"[Mesh] OR "Drug Costs"[Mesh] OR "Health Expenditures"[Mesh])
#24	Search "Health Services Accessibility"[Mesh]Â OR "Public Health/economics"[Mesh]
#25	#23 OR #24
#26	#10 AND #22 AND #25
#27	#26 AND Filter: Humans

Appendix Table A4. Inclusion/exclusion guide of the literature search.

Is the publication original research reporting primary data (NOT editorials, letters, non-systematic reviews, case-reports, case series)?	Yes (or cannot determine from title/abstract)	No STOP & EXCLUDE
Is the research in a low- or middle-income country? (NOT including any dependent states or territories of high-income countries)	Yes (or cannot determine from title/abstract)	No STOP & EXCLUDE
Does the study include an intervention related to the treatment of hypertension that: <ul style="list-style-type: none"> • Takes place in a clinical setting • Addresses management of chronic hypertension, including as part of an evaluation of a related morbidity • Does NOT involve surgery or acute hypertension-related events • Encourages lifestyle modification, provides pharmacological treatment, or improves access and affordability to diagnosis, treatment, and medication? 	Yes (or cannot determine from title/abstract)	No STOP & EXCLUDE
Does the study include cost-effectiveness, cost/benefit analysis, economic analysis, or similar analysis as an outcome or component of the study? NOT the cost of hypertension alone, without treatment or some type of intervention.	Yes (or cannot determine from title/abstract)	No STOP & EXCLUDE

Appendix Table A5. List of studies included in the review.

1. Adigun. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs.
2. Akici. Antihypertensive drug utilization at health centres in a district of Istanbul.
3. Akunne. Antihypertensive prescription among black patients without compelling indications: prescription, effectiveness, quality and cost of medication.
4. Alefan. Cost-Effectiveness of Antihypertensive Treatment in Malaysia.
5. Altagracia. Consumption and costs of antihypertensive drugs in Mexico: are diuretic agents a standing technological trajectory?
6. Amira. Antihypertensive pharmacotherapy in a developing economy: pattern, acquisition costs and conformity to international guidelines in a tertiary-care setting.
7. Anchala. Evaluation of effectiveness and cost-effectiveness of a clinical decision support system in managing hypertension in resource constrained primary health care settings: results from a cluster randomized trial.
8. Anderson, A Nixon. AT1 receptor blockers--cost-effectiveness within the South African context.
9. Anderson, Ian. The costs and affordability of drug treatments for type 2 diabetes and hypertension in Vanuatu.
10. Arredondo. Costs and financial consequences of the changing epidemiological profile in Mexico.
11. Augustovski. Cost Effectiveness of a Comprehensive Approach for Hypertension Control in Low-Income Settings in Argentina: Trial-Based Analysis of the Hypertension Control Program in Argentina.
12. Bai. Cost-Effectiveness of a Hypertension Control Intervention in Three Community Health Centers in China.
13. Basu. Alternative Strategies to Achieve Cardiovascular Mortality Goals in China and India: A Microsimulation of Target- Versus Risk-Based Blood Pressure Treatment.
14. Berrada. Trends in antihypertensives use among Moroccan patients.
15. Bueno. Objectively Measured Physical Activity and Healthcare Expenditures Related to Arterial Hypertension and Diabetes Mellitus in Older Adults: SABE Study.
16. Calvo-Vargas (1998). Changes in the costs of antihypertensive medications in a developing country: a study in Mexico comparing 1990 and 1996.
17. Calvo-Vargas (2001). Reproducibility and cost of blood pressure self-measurement using the 'Loaned Self-measurement Equipment Model'.
18. Catic. Outpatient antihypertensive drug utilization in Canton Sarajevo during five years period (2004-2008) and adherence to treatment guidelines assessment.
19. Cazarim. Cost-effectiveness analysis of pharmaceutical care for hypertensive patients from the perspective of the public health system in Brazil.
20. Chen. Potential health impact and cost-effectiveness of drug therapy for prehypertension.
21. Das. Clinical effectiveness and safety of low cost versus innovator brand amlodipine in hypertension: A single-blinded, randomized, crossover, noninferiority trial.
22. Day. The cost-effectiveness of managed care regarding chronic medicine prescriptions in a selected medical scheme.
23. Edwards. Improving cost-effectiveness of hypertension management at a community health centre.
24. Ekwunife. Cost-utility analysis of antihypertensive medications in Nigeria: a decision analysis.
25. Gad. Supporting the Development of Evidence-Informed Policy Options: An Economic Evaluation of Hypertension Management in Ghana.

26. Gaziano. Cost-effectiveness analysis of hypertension guidelines in South Africa: absolute risk versus blood pressure level.
27. Gu. The Cost-Effectiveness of Low-Cost Essential Antihypertensive Medicines for Hypertension Control in China: A Modelling Study.
28. Ha. Cost-Effectiveness Analysis of Interventions to Prevent Cardiovascular Disease in Vietnam.
29. He. Effect of a Community Health Worker–Led Multicomponent Intervention on Blood Pressure Control in Low-Income Patients in Argentina: A Randomized Clinical Trial.
30. Ilesanmi. The managed hypertensive: the costs of blood pressure control in a Nigerian town.
31. Ivanova. Hypertension and common complications --analysis of the ambulatory treatment cost.
32. Jafar. Cost-Effectiveness of Community-Based Strategies for Blood Pressure Control in a Low-Income Developing Country. Findings from a Cluster-Randomized, Factorial-Controlled Trial.
33. Jiang. Are services delivered by community health centers more cost-effective? Evidence from urban China.
34. Kasonde. Evaluating medicine prices, availability and affordability in Bangladesh using World Health Organisation and Health Action International methodology
35. Khatib. Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data.
36. Khonputsu. Generalized cost-effectiveness analysis of pharmaceutical interventions for primary prevention of cardiovascular disease in Thailand.
37. Kibirige. Access to medicines and diagnostic tests integral in the management of diabetes mellitus and cardiovascular diseases in Uganda: insights from the ACCODAD study.
38. Krishnan. Cost-effectiveness and budget impact of the community-based management of hypertension in Nepal study (COBIN): a retrospective analysis.
39. Le. The economic burden of hypertension in rural south-west China.
40. Lung. Fixed-combination, low-dose, triple-pill antihypertensive medication versus usual care in patients with mild-to-moderate hypertension in Sri Lanka: a within-trial and modelled economic evaluation of the TRIUMPH trial.
41. Makkink. Angiotensin converting enzyme inhibitors v. angiotensin receptor blockers in the management of hypertension: a funder's perspective.
42. Murray. Effectiveness and Costs of Interventions to Lower Systolic Blood Pressure and Cholesterol: A Global and Regional Analysis on Reduction of Cardiovascular-Disease Risk.
43. Ngalesoni. Cost-effectiveness of medical primary prevention strategies to reduce absolute risk of cardiovascular disease in Tanzania: a Markov modelling study.
44. Nguyen. Cost-Effectiveness Analysis of Screening for and Managing Identified Hypertension for Cardiovascular Disease Prevention in Vietnam.
45. Obreli-Neto. Economic evaluation of a pharmaceutical care program for elderly diabetic and hypertensive patients in primary health care: a 36-month randomized controlled clinical trial.
46. Ortegon. Cost effectiveness of strategies to combat cardiovascular disease, diabetes, and tobacco use in sub-Saharan Africa and South East Asia: mathematical modelling study.
47. Orubu. Access to essential cardiovascular medicines for children: a pilot study of availability, price and affordability in Nigeria.
48. Oyando. Patient costs of hypertension care in public health care facilities in Kenya.
49. Pandey. Financial Burden and Impoverishment Due to Cardiovascular Medications in Low and Middle Income Countries: An Illustration from India.
50. Pannarunothaai. Costs-effectiveness of the urban health center in Nakhon Ratchasima: a case study on diabetes and hypertension.
51. Patel. Cost-effectiveness analysis of nebivolol and metoprolol in essential hypertension: a pharmacoeconomic comparison of antihypertensive efficacy of beta blockers.

52. Perman. Cost-effectiveness of a hypertension management programme in an elderly population: a Markov model.
53. Praveen. Cardiovascular disease risk and comparison of different strategies for blood pressure management in rural India.
54. Rahmawati. Access to medicines for hypertension: a survey in rural Yogyakarta province, Indonesia.
55. Robberstad. Cost-effectiveness of medical interventions to prevent cardiovascular disease in a sub-Saharan African country—the case of Tanzania.
56. Rockers. Equity in access to non-communicable disease medicines: a cross-sectional study in Kenya.
57. Rosendaal. Costs and Cost-Effectiveness of Hypertension Screening and Treatment in Adults with Hypertension in Rural Nigeria in the Context of a Health Insurance Program.
58. Rubinstein. Estimation of the Burden of Cardiovascular Disease Attributable to Modifiable Risk Factors and Cost-Effectiveness Analysis of Preventative Interventions to Reduce This Burden in Argentina.
59. Subramanian. Cost and affordability of non-communicable disease screening, diagnosis and treatment in Kenya: Patient payments in the private and public sectors.
60. Syed. Access to Antihypertensive Medicines at the Household Level.
61. Tolla. Prevention and treatment of cardiovascular disease in Ethiopia: a cost-effectiveness analysis.
62. Tsuji. An economic evaluation of antihypertensive therapies based on clinical trials.
63. Twagirumukiza. Prices of antihypertensive medicines in sub-Saharan Africa and alignment to WHO's model list of essential medicines.
64. Verguet. Health Gains and Financial Risk Protection Afforded by Public Financing of Selected Interventions in Ethiopia: An Extended Cost-Effectiveness Analysis.
65. Wang, Xin. Effects and cost-effectiveness of a guideline-oriented primary healthcare hypertension management program in Beijing, China: results from a 1-year controlled trial.
66. Wang, Zengwu. Cost-effectiveness of nitrendipine and hydrochlorothiazide or metoprolol to treat hypertension in rural community health centers in China.
67. Xie. Cost-effectiveness analysis of intensive hypertension control in China.
68. Zeng (2013). A price and use comparison of generic versus originator cardiovascular medicines: a hospital study in Chongqing, China.
69. Zeng (2015). Review of ongoing initiatives to improve prescribing efficiency in China; angiotensin receptor blockers as a case history.
70. Zhao. Economic burden of obesity-related chronic diseases in Mainland China.
71. Pinto. Medicine prices and availability in the Brazilian Popular Pharmacy Program.

